BRIEF-Theratechnologies says 82.5 pct patients achieved primary endpoint in Phase III ibalizumab trial
May 24 (Reuters) - Theratechnologies Inc
* Theratechnologies announces that 82.5% of patients achieved the primary endpoint in the phase III ibalizumab trial
* Says taimed plans to submit an abstract to present these results at a major scientific conference later this year Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)
© Thomson Reuters 2017 All rights reserved.